You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.
Hard bargain or hardly a bargain?
The deadline for Medicare to announce negotiated prices on the first round of drugs is fast approaching. If you’re wondering how to tell whether the Biden administration drove a hard bargain, my colleague John Wilkerson has some tips.
Judging the negotiated prices is not straight forward, but there are at least four ways to get at it. Do they save taxpayers money? Do they save seniors’ money? Are they appropriately priced for the value they provide? Are we still paying more than other countries?
